Premium
Extended‐release guanfacine improves symptoms in adults with ADHD
Publication year - 2020
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30604
Subject(s) - guanfacine , agonist , attention deficit hyperactivity disorder , medicine , safety profile , anesthesia , psychiatry , adverse effect , pharmacology , clonidine , receptor
A Phase 3 study conducted in Japan has found that the extended‐release formulation of guanfacine improves symptoms of attention‐deficit/hyperactivity disorder (ADHD) in adults, without leading to major safety concerns. This is the first study to demonstrate in adults the efficacy and safety of the selective alpha‐2A adrenergic receptor agonist, which is used in the treatment of pediatric ADHD.